Dies ist eine Übersichtsseite mit Metadaten zu dieser wissenschaftlichen Arbeit. Der vollständige Artikel ist beim Verlag verfügbar.
Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck
5.087
Zitationen
17
Autoren
2006
Jahr
Abstract
BACKGROUND: We conducted a multinational, randomized study to compare radiotherapy alone with radiotherapy plus cetuximab, a monoclonal antibody against the epidermal growth factor receptor, in the treatment of locoregionally advanced squamous-cell carcinoma of the head and neck. METHODS: Patients with locoregionally advanced head and neck cancer were randomly assigned to treatment with high-dose radiotherapy alone (213 patients) or high-dose radiotherapy plus weekly cetuximab (211 patients) at an initial dose of 400 mg per square meter of body-surface area, followed by 250 mg per square meter weekly for the duration of radiotherapy. The primary end point was the duration of control of locoregional disease; secondary end points were overall survival, progression-free survival, the response rate, and safety. RESULTS: The median duration of locoregional control was 24.4 months among patients treated with cetuximab plus radiotherapy and 14.9 months among those given radiotherapy alone (hazard ratio for locoregional progression or death, 0.68; P=0.005). With a median follow-up of 54.0 months, the median duration of overall survival was 49.0 months among patients treated with combined therapy and 29.3 months among those treated with radiotherapy alone (hazard ratio for death, 0.74; P=0.03). Radiotherapy plus cetuximab significantly prolonged progression-free survival (hazard ratio for disease progression or death, 0.70; P=0.006). With the exception of acneiform rash and infusion reactions, the incidence of grade 3 or greater toxic effects, including mucositis, did not differ significantly between the two groups. CONCLUSIONS: Treatment of locoregionally advanced head and neck cancer with concomitant high-dose radiotherapy plus cetuximab improves locoregional control and reduces mortality without increasing the common toxic effects associated with radiotherapy to the head and neck. (ClinicalTrials.gov number, NCT00004227.)
Ähnliche Arbeiten
Human Papillomavirus and Survival of Patients with Oropharyngeal Cancer
2010 · 6.462 Zit.
Epidemiologic Classification of Human Papillomavirus Types Associated with Cervical Cancer
2003 · 6.273 Zit.
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
2016 · 5.002 Zit.
Head and neck squamous cell carcinoma
2020 · 3.929 Zit.
Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer
2008 · 3.696 Zit.
Autoren
Institutionen
- University of Alabama at Birmingham(US)
- University of Alabama at Birmingham Hospital(US)
- University of Wisconsin–Madison(US)
- Hebron University(PS)
- Merck (Germany)(DE)
- The University of Texas MD Anderson Cancer Center(US)
- University of Virginia(US)
- University of the Witwatersrand(ZA)
- University of Colorado Anschutz Medical Campus(US)
- Gdańsk Medical University(PL)